Realm Therapeutics - Presenting at Cowen Healthcare Conference

March 8, 2018
RNS Number : 0452H
Realm Therapeutics PLC
08 March 2018
 

Realm Therapeutics to Present at the Cowen and Company 38th Annual Health Care Conference

 

MALVERN, PA, March 8 2018 - Realm Therapeutics plc (AIM:RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, announced today that Alex Martin, CEO, will be presenting at the Cowen and Company 38th Annual Health Care Conference, on Tuesday, March 13, 2018 at 10:00 a.m. ET at the Boston Marriott Copley Place. 

 

A live and archived webcast of the Cowen presentation will be available on the Events and Presentations page of the Company's website. An updated copy of Realm's corporate presentation will be available on March 13 on the Company's website at www.realmtx.com

 

About Realm Therapeutics

 

Realm Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapeutics that target the intersection between innate and adaptive immunity, to influence immune signaling and to change the course of immune-mediated diseases in adults and children. Realm's lead drug development programs utilize the Company's proprietary immunomodulatory technology for the treatment of Allergic Conjunctivitis (PR013) and Atopic Dermatitis (PR022) and Realm is exploring its efficacy in Acne and additional Dermatology and Ophthalmology indications as well as other disease areas. For more information on Realm Therapeutics, Inc. please visit www.realmtx.com.

 

Forward Looking Statements

 

 

Contact:

Realm Therapeutics plc

Alex Martin, Chief Executive Officer

Marella Thorell, Chief Financial Officer and Chief Operating Officer

Outside US:  +44 (0) 20 3727 1000

US:  +1 212 600 1902

 

Argot Partners

Stephanie Marks

+1 212 600 1902

 

FTI Consulting

Simon Conway / Mo Noonan

+44 (0) 20 3727 1000

 

N+1 Singer (Nominated Adviser and Broker) Aubrey Powell / Jen Boorer

+44 (0) 20 7496 3000


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAEAPDXELAPEFF

Search Investor Relations